65 results about "Precancerous condition" patented technology

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention relates to the technical field of biological detection, and discloses a reagent composition and a kit for detecting cervical cancer and precancerous lesions of cervical cancer and application of the reagent composition and the kit. The reagent composition provided by the invention is used for detecting the methylation degree of a specific marker gene, and the detection sensitivity and specificity of cervical cancer and high-grade cervical cancer precancerous lesions are at a relatively high level. When the reagent composition is used for screening cervical cancer and precancerous lesions of HPV positive people, compared with conventional cytological detection, the colposcope referral rate is greatly reduced, meanwhile, the detection times for definite diagnosis of high-grade cervical lesions or cervical cancer are reduced, and the waste of medical resources and the examination burden of patients are reduced.

The invention belongs to the technical field of microorganisms, and particularly relates to combined lactobacillus salivarius and application thereof in female genital tract health. The preservation number of the strain is CCTCC NO: M20231719, and the strain has good bacteriostatic ability and dendritic cell (DC) maturation / activation stimulation ability, has no potential safety problem, can regulate vaginal micro-ecological balance, prevent infection caused by exogenous bacteria, effectively improve tumor immunosuppression microenvironment, and has good application prospects. And the method has very important significance on prevention / treatment of vaginal dysbacteriosis patients, gynecological tumors and precancerous lesions thereof.

The present disclosure provides an establishment and use of index for evaluating malignancy level of tissue microenvironment, which can be used to detect the potential of an individual to develop precancerous lesions and to predict the recurrence of tumors without relying on patient survival data.

The invention discloses a biomarker for accurate typing of esophageal squamous carcinoma lesion and application of the biomarker, and belongs to the technical field of molecular biology, the biomarker is SOX2 protein and KDM4B protein which are co-localized in nuclei, and the biomarker is applied to accurate typing of esophageal squamous carcinoma lesion with a non-diagnostic purpose. The cell proportion and distribution conditions of the SOX2 protein and the KDM4B protein are simultaneously displayed on the same section by adopting a double-label immunofluorescence method, and tests prove that the intranuclear co-localization of the SOX2 and the KDM4B can be used as an early warning mark and is used for identifying high-risk patients or early stages of precancerous lesions or distinguishing tumor patients, so that the missed diagnosis rate is reduced, and the diagnosis time is shortened. Therefore, a reliable basis is provided for accurate typing of esophageal squamous carcinoma lesions.

This invention discloses a wired dual-modal imaging capsule endoscopy system, belonging to the field of medical device technology. The system includes a capsule module, a transmission and control module, a dual-modal imaging module, and a signal analysis module. The capsule module is used to achieve 360° circumferential scanning imaging of the esophageal mucosa. The transmission and control module ensures stable transmission of optical and electrical signals and precise control of capsule movement. The dual-modal imaging module integrates an optical coherence tomography submodule and a photoacoustic imaging submodule to acquire tissue morphology information and microvascular distribution information, respectively. The signal analysis module processes the dual-modal signals. This invention achieves three-dimensional high-resolution integrated imaging of the esophageal mucosa without the need for exogenous labeling agents, significantly improving the detection accuracy of early esophageal cancer and precancerous lesions.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and at least one anti-cancer agent. It also relates to a process of preparing the composition and a method / use of the peptide alone or in combination with at least one anti-cancer agent in preventing or managing or treating cancer / precancerous condition.

The present invention provides a computer implemented method for the prediction of clinical outcomes in patients with cancer or pre-neoplastic conditions through the integration of genomic evolutionary, genomic and clinical. More specifically, the invention provides systems and algorithms that generate prognostic and predictive models based on the combined analysis of molecular features, inferred evolutionary routes, and clinical parameters, enabling patient risk stratification and individualized outcome estimation.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

The present invention relates to combination therapies for the treatment of cancer, the therapies comprising a piperazine derivative and a chemotherapeutic agent and / or a targeted therapy agent; methods of making such compounds; pharmaceutical compositions comprising such compounds; and methods of using these compounds, particularly methods for targeted therapy of hyperproliferative disorders, including benign hyperproliferative disorders, cancer, and precancerous conditions.

Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

This specification discloses methods for identifying stable control loci for use in fluorescence in situ hybridization (FISH) assays, and methods for determining whether copy number changes (e.g., amplification) of a target genomic locus (e.g., a gene, e.g., cyclin E1 (CCNE1)) have occurred in a biological sample (e.g., a non-neoplastic sample, a pre-neoplastic lesion, and / or a tumor). In particular, this disclosure provides an expanded repertoire of genomic loci that can serve as stable controls (e.g., stable control loci) for FISH assays aimed at determining copy number changes of a target genomic locus.

Aspects described herein may include a method of diagnosing cervical cancer and pre-cancer conditions, including: utilizing a computer to extract a numerical value corresponding to an order parameter squared (S2) from image data from at least one image of cervical tissue / cells from a patient, wherein the image data includes at least one region having light regions and dark regions, and wherein S2 includes a numerical value quantifying a degree of order present in the image data, and wherein the extracted numerical value comprises a ratio of an area of the light regions to a total area; comparing the extracted numerical value to one or more predefined diagnosis ranges corresponding to stages of cervical cancer and pre-cancer conditions; and diagnosing the stage of the cervical cancer and pre-cancer conditions if the numerical value of the S2 falls within one of the predefined diagnosis ranges.

The invention discloses a library construction method for non-HPV (human papillomavirus) related cervical tumor and precancerous lesion molecular subtypes thereof based on high-throughput sequencing, which comprises the following steps: ultrasonically breaking genome DNA (deoxyribonucleic acid) of a detected sample to obtain a DNA fragment, modifying the tail end, connecting a joint, and performing purification and pre-amplification reaction, namely performing hybridization reaction on a pre-amplification sequence by using a hybridization capture reagent, according to the method, a hybridization capture reagent is adopted, DNA fragments combined through non-specific capture are enriched and removed, then an amplification reaction is carried out, a library is obtained, next-generation sequencing is carried out, original data are subjected to bioinformatics analysis, variation information is obtained, and the hybridization capture reagent comprises specific primers with the sequences shown as SEQ ID NO: 1-175. According to the present invention, the integration of the non-HPV-related cervical tumor and precancerous lesion molecule detection is achieved, the detection can be completed in one experiment, and the sequencing depth is improved by specifically enriching the target region so as to improve the sensitivity of the non-HPV-related cervical tumor and precancerous lesion molecule detection.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The invention discloses a traditional Chinese medicine composition for treating intestinal tract diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 8-15 parts of selfheal, 20-40 parts of nacre mother of pearl, 5-10 parts of radix bupleuri, 3-8 parts of fried fructus aurantii, 3-8 parts of rhizoma cyperi, 6-12 parts of inula flower and 5-9 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition can be used for pertinently treating liver and gall stagnated heat, stomach qi reversal type bile reflux gastritis or gastroesophageal reflux disease, has the specific treatment effects of relieving inflammation, inhibiting local tissue angiogenesis and preventing precancerous lesions and / or canceration, and has good clinical significance.

The present invention relates to methods of sensitizing a subject having cancer or pre-cancer to treatment with immune checkpoint inhibitors, as well as agents for use in sensitizing a subject to such treatment.

This invention discloses a multimodal cervical precancerous lesion region segmentation method based on the Swin Transformer. The invention proposes the MSS-Net neural network to overcome the shortcomings of existing methods, fully utilizing the feature extraction capabilities of the Swin Transformer to achieve multimodal fusion of acetic acid and iodine test images. First, HSIL+ regions in colposcopy images are collected and labeled. Then, a target inspection algorithm is used to extract the cervical region, removing noise from non-cervical regions. Next, the preprocessed acetic acid and iodine solution images are input into the Swin Transformer feature extraction network to obtain multi-level feature maps. After weighted fusion of the feature maps through a multimodal attention module, the data is input into a decoder module, where cascaded upsampling generates the final segmentation result. Finally, the MSS-Net neural network is trained using the Dice coefficient and cross-entropy loss function to obtain the trained model. This invention achieves relatively accurate segmentation of cervical precancerous lesion regions through multimodal data fusion and enhanced feature extraction capabilities.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising a) detecting the presence or absence of an antibody to ANPEP (Aminopeptidase N, anti-ANPEP antibody) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the presence or absence of an antibody to ANPEP determined in step a). The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.

The invention relates to the technical field of molecule and cell biology, and discloses a preparation method of a polygene methylation detection kit based on fecal DNA, which comprises the following steps: preparing a specific primer and probe mixture: the mixture comprises specific primers and probes for detecting methylation states of BMP3, NDRG4, TFPI2, SDC2 and SFRP2 genes, and internal reference primers and probes for detecting ACTB genes; according to the invention, five genes of BMP3, NDRG4, TFPI2, SDC2 and SFRP2 are adopted for joint detection. The multi-gene combination strategy can effectively overcome the limitation that a single gene methylation signal is deleted or unstable in part of early cancer or precancerous lesions, and the detection rate (sensitivity) of colorectal cancer, especially early colorectal cancer, is greatly improved through multi-target and multi-channel coverage.

The invention discloses a multi-omics disease prediction model-based construction method, equipment, a medium and a program product, which are applied to the field of intelligent medical detection. The method comprises the following steps: preprocessing multi-omics original data; cross-omics association feature screening is performed through a dynamic feature selection mechanism fusing mutual information entropy, omics weight and KL divergence, and dynamic update features are dynamically generated based on local density and category weight; according to the method, multi-omics information can be effectively fused, the discrimination of feature selection, the training stability and the recognition capability of early gastric cancer and precancerous lesions are improved, and the method has relatively high clinical application value.

The invention provides an artificial-intelligence–based platform for automated analysis of Pap smear slides. The system integrates preprocessing, dual deep learning models (CNN-Transformer and EfficientNet-LSTM), and reporting modules to classify cytological images into diagnostic categories including NILM, ASC-US, LSIL, HSIL, and SCC. The platform includes interpretability outputs, secure data management, and active learning capabilities, enabling scalable, accurate, and transparent cervical-cancer screening across diverse laboratory settings. The platform is suitable for implementation in clinical pathology laboratories, telemedicine networks, and population-level screening programs. It allows rapid, reproducible, and objective evaluation of cytology slides, improving throughput while reducing reliance on manual slide examination. The invention is deployable on local servers, private clouds, or public cloud infrastructures and is adaptable to various cytology specimens. Adoption of this system enhances early detection of precancerous lesions, reduces inter-observer variability, and facilitates integration with laboratory information systems. It also supports continuous learning and adaptation to evolving imaging protocols. The invention provides multiple advantages over existing methods: (1) Dual-model architecture combining CNN-Transformer and EfficientNet- LSTM ensures robust classification across both dense and sparse cellular regions. (2)Preprocessing and adaptive tiling improve feature extraction from variable-quality images. (3)Interpretability modules enhance clinician trust and facilitate regulatory compliance. (4) Active learning allows continuous improvement based on expert feedback. (5) Modular deployment supports both local laboratory and cloud-based operation. (6) Data security features meet international standards for privacy and encryption. (7) High scalability enables screening of large slide volumes without compromising accuracy. The invention provides a clinically relevant, efficient, and technologically advanced solution for automated cervical-cancer screening, applicable in diverse healthcare environments and adaptable to future cytology domains.

Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L 1 therapy.

The present application relates to the field of traditional Chinese medicine, and particularly to a composition for treating chronic gastritis and application thereof, the composition is prepared from the following raw materials according to weight fraction: 8-12 parts of Fashanxia, 8-12 parts of Huangqin, 3-7 parts of Huanglian, 4-8 parts of Ganjiang, 12-18 parts of Taizishen, 12-18 parts of Baihuasheshecao, 12-16 parts of Banzhilian, 8-12 parts of E'zhu, 12-20 parts of Chaozhigu, 18-22 parts of Chaoquya, 18-22 parts of Chaomaiya, 8-12 parts of Yujin, 1-5 parts of Sanqi, 8-12 parts of Dazao and 3-8 parts of Zhigancao. The present application effectively solves the problems of lack of specific therapy and specific intervention target for reversing mucosal atrophy, intestinal metaplasia and other precancerous lesions in the prior art, provides a new idea for the mechanism research of CAG treatment by traditional Chinese medicine, and has important theoretical value and clinical conversion prospect for promoting the modernization of traditional Chinese medicine.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level CLEC3B (C-type lectin domain family 3 member B) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of CLEC3B determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

Provided are methods for preventing initiation and / or progression of gastrin-associated tumors and / or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and / or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and / or development of a gastrin-associated tumor or cancer and / or for preparing medicaments therefor, and compositions for use in preventing initiation and / or development of gastrin-associated tumors and / or cancers and / or precancerous lesions thereof.